Dr. Pratap Basim is currently working as a Supervisor of Formulation and Process Development, Product Development Services at Thermo Fisher Scientific, Cincinnati, OH, USA. He obtained his Ph.D. in Pharmaceutics from Long Island University at Brooklyn, NY, and has 5+ years of industrial experience working for small and large size pharmaceutical companies. He is a member of scientific societies including American Association of Pharmaceutical Scientists, Compaction Simulation Forum, etc. He is a reviewer for International Journal of Pharmaceutics, Drug Development and Industrial Pharmacy, AAPS PharmSciTech, Biomolecules, 3 Biotech, etc. He has published many research papers and book chapters in internationally well-known peer reviewed journals. He is also serving in the editorial board of many renowned Journals.

Research Interest: Immunogenicity, PK, Biomarker, Regulated and non regulated bioanalysis.

After graduation I started to work at Medical University of Silesia, where I completed my PhD thesis on genetic polymorphisms in coronary artery disease. Selected risk factors for development of arterial ischemic stroke in children were also in the area of my scientific interests. Besides, I am also interested in diagnosis and treatment of other neurological disorders in children: schizencephaly, headache, epilepsy and cerebral palsy. Nine years ago, when I moved to the Department of Pharmaceutical Technology I started the research concerning the technology for the manufacturing and optimization of micro- and nanocarriers of active substances. In addition, I am involved in analyses of rheological parameters of semi-solid preparations.

Research Interest: developmental neurology, neuroscience, genetics, pharmaceutical technology, nanotechnology, biochemistry

Grants: I participated in a multi-center Polish scientific grant and in several academic grants. In 2017, I was a supervisor of a grant of Medical University of Silesia regarding the release of active substances from semi-solid bases.

List of Publications:
Selected articles of my authorship:
1. Beata Sarecka-Hujar, Ilona Kopyta. Poststroke epilepsy: current perspectives on diagnosis and treatment. Neuropsychiatr.Dis.Treat. 2019; Vol.15, p.95-103

2. Joanna Sordyl, Ilona Kopyta, Beata Sarecka-Hujar, Tomasz Francuz, Paweł Matusik, Ewa Małecka-Tendera. Lipid levels and selected biomarkers of vascular changes in children with idiopathic headaches - a preliminary report. Arch.Med.Sci. 2019; Vol.15, No.1, p.120-125

3. Beata Sarecka-Hujar, Andrzej Jankowski, Aneta Ostróżka-Cieślik, Radosław Balwierz, Anna Banyś, Renata Dyja, Dariusz Łukowiec, Dominik Marciniak, Janusz Pluta. Assessment of release of trimetazidine hydrochloride from orally disintegrating tablets (ODTs) prepared using different disintegrants. Acta Pol.Pharm.-Drug Res. 2018; Vol.75, No.3, p.697-704

4. Aneta Ostróżka-Cieślik, Beata Sarecka-Hujar, Tomasz Krzykawski, Jagna Karcz, Anna Banyś, Andrzej Jankowski. Application of selected diffractive and microscopic methods to evaluate the physical state of drug and morphology of microspheres obtained by spray drying of furosemide with Eudragit L30 D-55. Acta Pol.Pharm.-Drug Res. 2018; Vol.75, No.3, p.759-765

5. Beata Sarecka-Hujar, Ilona Kopyta, Michał Skrzypek. Is the 1298A>C polymorphism in the MTHFR gene a risk factor for arterial ischaemic stroke in children? The results of meta.analysis. Clin.Exp.Med. 2018; Vol.18, No.3, p.337-345. 

6. Aneta Ostróżka-Cieślik, Beata Sarecka-Hujar, Andrzej Jankowski. Physicochemical characteristics of furosemide incorporated Eudragit microspheres formulated by spray drying. Acta Pol.Pharm.-Drug Res. 2018; Vol.75, No.6, p.1369-1376

7. Beata Sarecka-Hujar, Radosław Balwierz, Aneta Ostróżka-Cieślik, Renata Dyja, Dariusz Łukowiec, Andrzej Jankowski. Scanning electron microscopy and X-ray energy dispersive spectroscopy - useful tools in the analysis of pharmaceutical products. J.Phys.: Conf.Series 2017; Vol.931, 012008, p.1-5

8. Andrzej Jankowski, Renata Dyja, Beata Sarecka-Hujar. Dermal and transdermal delivery of active substances from semisolid bases. Indian J.Pharmaceut.Sci. 2017; Vol.79, No.4, p.488-500

9. Aneta Ostróżka-Cieślik, Beata Sarecka-Hujar. The use of nanotechnology in modern pharmacotherapy. In: Multifunctional systems for combined delivery, biosensing and diagnostics. / Editors: Alexandru Mihai Grumezescu, Amsterdam: Elsevier Inc., 2017, p. 139-158, ISBN: 978-0-323-52725-5

10. Aneta Ostróżka-Cieślik, Beata Sarecka-Hujar. Perspectives of the carbon nanoparticles use in cancer therapy and imaging. Post.Biol.Kom. 2017; T.44, nr 2, s.171-184

11. Dorota Raczkiewicz, Beata Sarecka-Hujar, Alfred Owoc, Iwona Bojar. Cognitive functions and serum cortisol concentration in perimenopausal and postmenopausal women working non-manually. Neuroendocrinol.Lett. 2017; Vol.38, No.4, p.269-274

12. Dorota Raczkiewicz, Alfred Owoc, Beata Sarecka-Hujar, Iwona Bojar. Pain involving the motor system and serum vitamin D concentration in postmenopausal women working in agriculture. Ann.Agric.Environ.Med. 2017; Vol.24, No.1, p.151-155

13. Beata Sarecka-Hujar, Ilona Kopyta, Michał Skrzypek, J. Sordyl. Association between the 20210G>A prothrombin gene polymorphism and arterial ischemic stroke in children and young adults - two meta-analyses of 3586 cases and 6440 control subjects in total. Pediatr.Neurol. 2017; Vol.69, p.93-101

14. Beata Sarecka-Hujar, Aneta Ostróżka-Cieślik, Anna Banyś. Determinants of telemedicine development in health care system. Ann.Acad.Med.Siles. 2016; Vol.70, s.214-219

15. Ilona Kopyta, Paweł Niemiec, Anna Balcerzyk, Ewa Emich-Widera, Ewa Pilarska, Karolina Pienczk-Recławowicz, Marek Kaciński, Janusz Wendorff, Tomasz Nowak, Tomasz Iwanicki, Beata Sarecka-Hujar, Iwona Żak. Fibrinogen alpha and beta gene polymorphisms in pediatric stroke - Case-control and family based study. Eur.J.Paediatr.Neurol.2015; Vol.19, No.2, p.176-180

16. Ilona Kopyta, Mikołaj Zimny, Beata Sarecka-Hujar. The role of biochemical risk factors in the etiology of AIS in children and adults. Int.J.Neurosci.2015; Vol.125, No.12, p.875-884

17. Anna Banyś, Beata Sarecka-Hujar, Andrzej Jankowski, Monika Zalewska. Impact of base type on diclofenac sodium release from semi-solid dosage forms. Ann.Acad.Med.Siles. 2014; Vol.68, No.1, s.1-8

18. Ilona Kopyta, Beata Sarecka-Hujar, Joanna Sordyl, Ryszard Sordyl. The role of genetic risk factors in arterial ischemic stroke in pediatric and adult patients: a critical review. Mol.Biol.Rep. 2014; Vol.41, No.7, p.4241-4251

19. Beata Sarecka-Hujar, Iwona Żak, Ewa Emich-Widera et al. Association analysis of the E-selectin 98G>T polymorphism and the risk of childhood ischemic stroke. Cell Biochem. Funct. 2010; 28: 591-596.

20. Ilona Kopyta, Beata Sarecka-Hujar, Ewa Emich-Widera et al. Association between lipids and fibrinogen levels and ischemic stroke in the population of the Polish children with arteriopathy and cardiac disorders. Wiad. Lek. 2010; 63:17-23.  

21. Zak I, Sarecka-Hujar B, Kopyta I et al. The T allele of the 677C>T polymorphism of methylenetetrahydrofolate reductase gene is associated with an increased risk of ischemic stroke in Polish children. J Child Neurol. 2009; 24: 1262-1267. 

22. Sarecka-Hujar B, Zak I, Krauze J. Interactions between rs5498 polymorphism in the ICAM1 gene and traditional risk factors influence susceptibility to coronary artery disease. Clin Exp Med. 2009; 9: 117-124.

Research Interest: Drug Delivery, Continuous manufacturing, Dissolutions, Solubility, Cocrystalisation, Hot-Melt Extrusion, Particle Engineering, Medical Implants, Solid-State Analysis, PAT, QbD, Spray Drying, Process Engineering.

Research Interest: Biomaterials, Nanomedicine, Pharmaceutical Nanotechnology, Nanovaccines, Targeted drug delivery, Nanotoxicity, surface biofunctionalization, Cell-nanoparticle Interactions.

Research Interest: Expression Microarrays, Next Generation Sequencin, Liquid Handling Robotics, cDNA Synthesis, RNA Isolation, Splicing, PCR, Gene Expressio, Cell Cultur, Molecular Cloning, Regulation of Gene Expression, RNA Biology, Transcriptomics, Gel Electrophoresis, RNA Splicing.

Research Interest: Systems Pharmacology, Drug Metabolism & Drug Transport, Pharmacokinetics/Pharmacometrics, Pharmacogenomics, Nanomedicine and Chinese Medicine.

Research Interest: Abuse-Deterrent Formulations (Tamper-Resistant Pharmaceutical Dosage Forms) Gastric Retention, Oral Drug Delivery, Controlled Drug Delivery Systems and Technologies, Gels, Hydrogels, Alcogels, Pharmacy Compounding.

Research Interest: Design, Synthesis and qualitative SAR of new anticonvulsant agents acting as non-competitive AMPA receptor antagonists (In collaboration with Dr. Li Niu, Chemistry Department, University at Albany, SUNY, Albany NY), Identifications and synthesis of new anti-cancer agents, Design and synthesis of peptidomimetics as protease inhibitors.

Research Interest: Reactive Oxygen Species, Apoptosis, Signaling Pathways, Western Blot, Phosphorylation, Superoxide Dismutase, NADPH Oxidase, Monocytes

Research Interest: Natural products chemistry (including extraction and separation of compounds and structure elucidation), Discovery and biological investigation of novel drug lead compounds from plant and microbial biodiversity, Botanical dietary supplements and functional foods research and evaluation of natural product-based botanical medicines, Quality control, pharmacokinetics and in vivo metabolism of Traditional Chinese Medicine.

Research Interest: Organic & Biomolecular Chemistry, Department of Pharmacy.

Research Interest: Bioactive constituents from natural resources, Quality control methods of natural medicines, Anaphylactoid constituents of herbal injections, R&D of new natural medicines.

Mehraliyeva Sevil Jabrayil graduated from the Faculty of Pharmacy of Azerbaijan State Medical Institute named after N.Narimanov in 1989 with honors diploma. was elected to the position and is currently working in this position.

 In 2010, S.J.Mehraliyeva defended her dissertation on the topic "Development of the technology for obtaining medicinal forms from some multicomponent plant assemblies and studying their biopharmaceutical properties", in 2011 she received the diploma of Doctor of Philosophy in Pharmacy, and in 2014 she received the scientific title of associate professor.

 Sevil Mehraliyeva is a member of the "Problem Commission on Pharmacy and Chemistry", 224156-Specialized Council for master's defense in "Pharmaceutical technology". He participated in the congresses held in 2020-2022, including training on Good Clinical Practice and received a certificate. In February 2022, he completed an internship at DAYTAM, Atatürk University of the Republic of Turkey.

Sevil Mehraliyeva made oral presentations at conferences held in the Republics of Azerbaijan, Russia, and Turkey during the period of her scientific research and was awarded certificates.

For the first time, Sevil Mehraliyeva developed immunotropic granules based on various phytocompositions, dental gel with anti-aging effect, anti-aging cream, anti-seborrheic shampoo, microcapsules for the treatment of atherosclerosis, anti-acne niosomal gel technology, and was awarded Azerbaijan and Eurasian patents (2017). -2022).

Since 2020, Mehraliyeva Sevil Jabrail has been working on her doctoral dissertation on the topic "Development of technology for obtaining nano-forms of medicine based on raw materials of natural origin".

According to the subject of his doctoral dissertation, he developed the technology of extraction from deer antlers grown in Azerbaijan for the first time. The technology of obtaining nanocapsules for the treatment of Alzheimer's, nanoemulsion and nanogel for the treatment of osteoporosis on the basis of this extract and the acquisition of an Azerbaijani patent in this field belong to Sevil Mehraliyeva (2021-2024).

In 2023-24, Sevil Mehraliyeva carried out the method of separating the actinide enzyme, which accelerates the digestion process, from the Chinese actinidia fruits grown in Azerbaijan and the microencapsulation of this enzyme.

Sevil Mehraliyeva also performed the technology of separating rutin from Japanese sophora buds and hop cones and preparing phytosomes based on rutin. Based on these phytosomes, the preparation of phytosomal gel with an effective effect in the treatment of periodontitis and the study of quality criteria were performed by Sevil Mehraliyeva (2024).

Research Interests: pharmaceutical technology, phyto- and animal medicinal technology, nanotechnology, nanocosmetology, nano- and micropharmaceutical medicinals, biopolymer technology, new drug delivery systems, including stomatological drug delivery systems.